Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment

Maria Cristina Leonardi¹, Giovanni Battista Ivaldi², Luigi Santoro³, Roberta Lazzari¹, Annamaria Ferrari¹, Anna Morra¹, Pietro Caldarella⁴, Loredana Burgoa⁵, Fabio Domenico Bassi⁴, Claudia Sangalli⁴, Nicole Rotmensz³, Alberto Luini⁴, Umberto Veronesi⁶, and Roberto Orecchia^{1,7}

¹Division of Radiation Oncology, European Institute of Oncology, Milan; ²Radiotherapy Department, Fondazione Salvatore Maugeri, Pavia; ³Division of Epidemiology and Biostatistics, and ⁴Division of Breast Surgery, European Institute of Oncology, Milan; ⁵Division of Surgery and Senology, General Hospital, Bergamo; ⁶Scientific Directorate, European Institute of Oncology, Milan; ⁷University of Milan, Milan, Italy

ABSTRACT

Aims. To evaluate late toxicity and cosmetic outcome after intraoperative radiotherapy using electrons (ELIOT) as sole treatment modality in early breast cancer patients.

Methods. A total of 119 patients selected randomly among 1200 cases was analyzed. Late toxicities were documented using the LENT-SOMA scoring system, cosmesis was evaluated with the Harvard scale, and a numeric rating scale was used to assess symptoms.

Results. After a median follow-up of 71 months, grade II fibrosis was observed in 38 patients (31.9%) and grade III fibrosis in 7 patients (5.9%). Postoperative complications (12.6%) did not correlate with late toxicity. Physicians and patients scored cosmesis as excellent or good in 84% and 77.3% of the cases, respectively. Patient satisfaction was higher than 90%.

Conclusions. In the study, ELIOT gives low and acceptable long-term toxicity. A longer follow-up and a larger number of patients are needed to confirm these promising results.

Key words: intraoperative radiotherapy with electrons, late toxicity, partial breast irradiation.

Conflict of interest statement: All authors disclose that there are no actual or potential conflicts of interest.

Acknowledgments: The authors thank AIRC (Associazione Italiana Ricerca sul Cancro) for their invaluable support for the ELIOT studies. The authors thank Mrs Anne Fraser for Revision of the English.

Correspondence to: Maria Cristina Leonardi, MD, Division of Radiation Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel +39-02-57489037; fax +39-02-94379227; email cristina.leonardi@ieo.it

Received July 7, 2011; accepted September 20, 2011.